Dr. Reddy's Laboratories Limited

NYSE:RDY

Drug Manufacturers - Specialty & Generic

Healthcare
$14.98 -1.13%

-$0.15 today

Market cap
$12.48B
Beta
0.26
P/E (TTM)
24.7
EPS (TTM)
$51.40
Dividend yield
0.63%
52W Low $12.19High $15.71

Volume 1.79M

Average 2.39M

RDY Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Dr. Reddy's Laboratories LimitedNYSE: RDY

Cash & Equivalents · Q2 FY2027 · quarter ended Sep 2026

Cash & equivalents rises 34.8% from a year ago

Cash & equivalents stood at ₹13.35B at the end of Q2 FY2027, up 34.8% from a year earlier and up 19.2% from the prior quarter. Over 3 fiscal years it compounded at +37.6% a year.

Context

  • Cash & equivalents amounted to 2.3% of total assets at the end of Q2 FY2027, up 0.5 pp from a year earlier.
  • Cash & equivalents increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +34.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
₹13.35B+19.2% QoQ
Last fiscal yearMar 2026
₹15.06B+2.8% YoY
Year agoSep 2025
₹9.91B+34.8% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+34.8%——
1 year+2.8%——
3-year CAGR+37.6%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

INR · from the balance sheet

Latest · FY2026
15.06B INR
Year-over-year change
+2.8%
4-year CAGR
+0.4%

Cash & Equivalents vs competitors

How RDY compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +34.8% is the 5th highest of 8, against a peer median of +56.5%.
  • Cash & equivalents amounts to 2.3% of total assets for RDY, versus a peer median of 7.4%.
RDY Competitors
Cash & Equivalents for RDY and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RDYDr. Reddy's Laboratories LimitedSep 2026₹13.35B INR+34.8%+37.6%2.3%
TEVATeva Pharmaceutical Industries LimitedJun 2026$3.66B USD+69.1%+8.3%9.2%
BHCBausch Health Companies Inc.Jun 2026$1.83B USD+5.7%+32.9%7.4%
HLNHaleon plcDec 2025£1.32B GBP-39.8%+24.6%4.1%
VTRSViatris Inc.Jun 2026$886.5M USD+56.5%+2.3%2.5%
ANIPANI Pharmaceuticals, Inc.Mar 2026$311.18M USD+107.7%+80.9%21.9%
AMPHAmphastar Pharmaceuticals, Inc.Mar 2026$171.17M USD-6.4%+2.9%10.4%
AMRXAmneal Pharmaceuticals, Inc.Jun 2026$127.64M USD+57.2%+128.7%3.4%
Peer median (excluding RDY) —+56.5%+24.6%7.4%

Competitors are the stored peer set for RDY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

INR
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Cash & Equivalents14.85B5.78B7.11B14.65B15.06B
Short-term Investments29.51B56.02B74.36B43.25B71.01B
Net Receivables80.27B83.2B95.34B109.79B99.22B
Inventory50.88B48.67B63.55B71.09B75.02B
Other Current Assets5.2B6.41B2.94B4.56B35.69B
Total Current Assets181.86B204.25B248.05B250.11B296B
Property, Plant & Equipment (Net)62.17B66.46B76.89B97.76B113.63B
Goodwill4.42B4.25B4.25B11.81B12.64B
Intangible Assets27.25B30.85B36.95B96.8B102.98B
Long-term Investments7.99B5.36B5.26B15.2B16.04B
Tax Assets8.2B7.2B10.77B18.51B21.99B
Other Non-current Assets948M3.49B5.35B2.79B4.59B
Total Non-current Assets110.97B117.6B139.47B242.88B271.88B
Total Assets292.83B321.85B387.52B492.99B567.88B
Account Payables15.97B17.86B21.55B20.05B32.75B
Short-term Debt27.08B11.19B12.72B38.05B63.85B
Tax Payables1.62B2.14B2.34B3.03B0
Deferred Revenue2.58B1.98B1.44B1.98B0
Other Current Liabilities6.76B9.19B11.42B13.52B63.43B
Total Current Liabilities94.02B85.85B96.04B130.39B164.25B
Long-term Debt3.8B03.8B3.8B11.96B
Deferred Tax Liabilities60M833M909M14.11B15.26B
Deferred Revenue (Non-current)1.6B1.56B1.19B1.16B0
Other Non-current Liabilities882M1.35B2.84B2.3B3.48B
Total Non-current Liabilities8.29B5.02B10.93B25.43B30.7B
Total Liabilities102.3B90.86B106.97B155.82B194.95B
Common Stock832M833M834M834M818.47M
Retained Earnings175.71B215.59B265.26B315.79B345.02B
Accumulated OCI755M886M653M3.98B10.5B
Other Stockholders Equity5.07B4.71B3.86B3.74B3.9B
Minority Interest0003.78B3.33B
Total Equity190.53B230.99B280.55B337.17B372.92B
Total Debt33.85B13.47B20.02B46.77B75.81B
Net Debt18.99B7.69B12.91B32.11B60.75B

Dr. Reddy's Laboratories Limited

NYSE:RDY

Intrinsic Alpha fair value

Locked

Current Price

$14.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.